The University of Chicago Header Logo

Connection

Peter Sand to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Peter Sand has written about Treatment Outcome.
Peter Sand
Connection Strength
1.520
Treatment Outcome
  1. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology. 2021 11; 157:71-78.
    View in: PubMed
    Score: 0.082
  2. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2019 08; 30(8):1253-1259.
    View in: PubMed
    Score: 0.069
  3. A multicenter, prospective trial to evaluate mesh-augmented sacrospinous hysteropexy for uterovaginal prolapse. Int Urogynecol J. 2015 May; 26(5):743-8.
    View in: PubMed
    Score: 0.052
  4. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep; 190(3):958-64.
    View in: PubMed
    Score: 0.046
  5. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013 Feb; 24(2):303-11.
    View in: PubMed
    Score: 0.044
  6. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012 Feb 01; 29(2):119-31.
    View in: PubMed
    Score: 0.043
  7. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
    View in: PubMed
    Score: 0.042
  8. Foreign-body granuloma after injection of calcium hydroxylapatite for type III stress urinary incontinence. Obstet Gynecol. 2011 Aug; 118(2 Pt 2):418-421.
    View in: PubMed
    Score: 0.041
  9. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
    View in: PubMed
    Score: 0.040
  10. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
    View in: PubMed
    Score: 0.039
  11. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010 Sep; 106(6):816-21.
    View in: PubMed
    Score: 0.037
  12. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010 Mar-Apr; 13(2):251-7.
    View in: PubMed
    Score: 0.037
  13. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
    View in: PubMed
    Score: 0.035
  14. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
    View in: PubMed
    Score: 0.035
  15. Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol. 2008 Dec; 199(6):696.e1-7.
    View in: PubMed
    Score: 0.034
  16. Subjective measures of efficacy and quality of life in overactive bladder syndrome. Curr Urol Rep. 2008 Sep; 9(5):368-72.
    View in: PubMed
    Score: 0.034
  17. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008 Jan; 71(1):57-61.
    View in: PubMed
    Score: 0.032
  18. Evaluation and treatment of female urinary incontinence. Minerva Urol Nefrol. 2007 Dec; 59(4):431-50.
    View in: PubMed
    Score: 0.032
  19. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007 Feb; 99(2):247-62.
    View in: PubMed
    Score: 0.030
  20. Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings. Neurourol Urodyn. 2007; 26(1):42-5.
    View in: PubMed
    Score: 0.030
  21. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
    View in: PubMed
    Score: 0.030
  22. Detrusor overactivity and urge urinary incontinence [corrected] following midurethral versus bladder sling procedures. Am J Obstet Gynecol. 2005 Dec; 193(6):2144-8.
    View in: PubMed
    Score: 0.028
  23. Factors influencing the long-term success of periurethral collagen therapy in the office. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jun; 17(4):346-51.
    View in: PubMed
    Score: 0.028
  24. A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol. 2005 May; 192(5):1649-54.
    View in: PubMed
    Score: 0.027
  25. Site-specific rectocele repair compared with standard posterior colporrhaphy. Obstet Gynecol. 2005 Feb; 105(2):314-8.
    View in: PubMed
    Score: 0.026
  26. Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.
    View in: PubMed
    Score: 0.026
  27. Foley versus intermittent self-catheterization after transvaginal sling surgery: which works best? Urology. 2004 Jul; 64(1):53-7.
    View in: PubMed
    Score: 0.025
  28. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug; 15(4):243-8.
    View in: PubMed
    Score: 0.025
  29. A randomized controlled trial comparing a modified Burch procedure and a suburethral sling: long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Oct; 14(4):229-33; discussion 233.
    View in: PubMed
    Score: 0.024
  30. A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS). Neurourol Urodyn. 2023 03; 42(3):615-622.
    View in: PubMed
    Score: 0.023
  31. Transvaginal Mesh Compared With Native Tissue Repair for Pelvic Organ Prolapse. Obstet Gynecol. 2022 06 01; 139(6):975-985.
    View in: PubMed
    Score: 0.022
  32. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol. 2001 Jun; 184(7):1357-62; discussion 1362-4.
    View in: PubMed
    Score: 0.021
  33. Children Treated for Nonsyndromic Craniosynostosis Exhibit Average Adaptive Behavior Skills with Only Minor Shortcomings. Plast Reconstr Surg. 2021 02 01; 147(2):453-464.
    View in: PubMed
    Score: 0.020
  34. Transvaginal therapy of genuine stress incontinence. Urology. 2000 Dec 04; 56(6 Suppl 1):23-7.
    View in: PubMed
    Score: 0.020
  35. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019 Sep; 131:77-82.
    View in: PubMed
    Score: 0.018
  36. Anterior Colporrhaphy With and Without Dermal Allograft: A Randomized Control Trial With Long-Term Follow-Up. Female Pelvic Med Reconstr Surg. 2019 May-Jun; 25(3):206-212.
    View in: PubMed
    Score: 0.018
  37. The Cognitive Profile of Children with Nonsyndromic Craniosynostosis. Plast Reconstr Surg. 2019 05; 143(5):1037e-1052e.
    View in: PubMed
    Score: 0.018
  38. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019 05; 201(5):967-972.
    View in: PubMed
    Score: 0.018
  39. Effect of a urinary control insert on quality of life in incontinent women. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10(2):100-5.
    View in: PubMed
    Score: 0.017
  40. Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019 02; 38(2):825-837.
    View in: PubMed
    Score: 0.017
  41. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997;49(Suppl 5A):93-99. J Womens Health. 1998 Mar; 7(2):268-9.
    View in: PubMed
    Score: 0.016
  42. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct. 1998; 9(2):100-2.
    View in: PubMed
    Score: 0.016
  43. Pelvic floor electrical stimulation for genuine stress incontinence: who will benefit and when? Int Urogynecol J Pelvic Floor Dysfunct. 1998; 9(5):265-70.
    View in: PubMed
    Score: 0.016
  44. Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. Int Urogynecol J. 2017 Sep; 28(9):1335-1340.
    View in: PubMed
    Score: 0.015
  45. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
    View in: PubMed
    Score: 0.014
  46. Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. Am J Obstet Gynecol. 1995 Jul; 173(1):72-9.
    View in: PubMed
    Score: 0.014
  47. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015 Jan; 34(1):37-43.
    View in: PubMed
    Score: 0.012
  48. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun; 189(6):2186-93.
    View in: PubMed
    Score: 0.011
  49. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
    View in: PubMed
    Score: 0.011
  50. Two unusual presentations of bladder diverticula. Obstet Gynecol. 2011 Aug; 118(2 Pt 2):415-417.
    View in: PubMed
    Score: 0.010
  51. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
    View in: PubMed
    Score: 0.010
  52. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
    View in: PubMed
    Score: 0.009
  53. Arcus-anchored acellular dermal graft compared to anterior colporrhaphy for stage II cystoceles and beyond. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Oct; 20(10):1265-71.
    View in: PubMed
    Score: 0.009
  54. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
    View in: PubMed
    Score: 0.008
  55. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007 May; 69(5):876-80.
    View in: PubMed
    Score: 0.008
  56. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
    View in: PubMed
    Score: 0.008
  57. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
    View in: PubMed
    Score: 0.007
  58. TVT versus SPARC: comparison of outcomes for two midurethral tape procedures. Int Urogynecol J Pelvic Floor Dysfunct. 2006 Feb; 17(2):125-30.
    View in: PubMed
    Score: 0.007
  59. Incidence of pubic osteomyelitis after bladder neck suspension using bone anchors. Urology. 2004 Apr; 63(4):704-8.
    View in: PubMed
    Score: 0.006
  60. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
    View in: PubMed
    Score: 0.006
  61. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
    View in: PubMed
    Score: 0.006
  62. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
    View in: PubMed
    Score: 0.005
  63. Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. Urology. 2000 Dec 04; 56(6 Suppl 1):82-6.
    View in: PubMed
    Score: 0.005
  64. Pelvic floor electrical stimulation for the treatment of urge and mixed urinary incontinence in women. Urology. 1997 Dec; 50(6):934-40.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.